SLIDE 1
1
27 February 2013 Ticker : ige Web : www.ish.co.uk
2013 ANNUAL GENERAL MEETING
SLIDE 2 2
Company Overview
- Shares in issue 76,267,932
- Market Cap £1.24m @ 1.62p per share
- Est .1996 acquiring IP from Nottingham Trent University
- Floated on AIM in 2002 on back of 3D x-ray technology
- Operates in Security and Industrial inspection markets
- Security portfolio includes a range of portable, baggage
and vehicle x-ray screening products
- Industrial applications include x-ray inspection of
catalytic converters, batteries and medical devices
- Maiden profit in 2012
- Employs 20 staff based near Loughborough
AXIS-3D
SLIDE 3 3
Experienced Management
Chairman
Chief Executive Officer
Chief Technical Officer appointment as NED from11th June 2013
Sales and Marketing Director appointed 1st January 2013
Non-Executive Director
SLIDE 4 4
Investor Opportunity
- Company has a diversified portfolio of products across two sectors
- With national and international reach and blue-chip customers
- The Company has a well-qualified, experienced and balanced Board
- Finances have been well managed and costs controlled
- Revenue doubled and maiden profit achieved in tough economic
climate
- Opportunity to participate in AIM-listed British technology company
- Image Scan remains low investment threshold stock
SLIDE 5 5
Low Investment Threshold
- Sustainability of business performance
remains a challenge and a priority
- Company continues to be more sales
and marketing driven
- Extension of product range driven by
end user and customer feedback
- Contracts drawn from wider range of
customers and territories
- Appointed Financial PR advisers
2 4 6 8 10 12 14 16 18 20
Pence
2004 2006 2008 2010 2012
3 0 S e pte mbe r
Share Price
Share-holding Share- holding Rise Step Int’l Dev 26.05% D Allenby 8.08% Calculus Capital 7.30% A P Stirling 4.94% Directors 4.12%
SLIDE 6 6
FY12 Highlights
- Revenue doubled to £4.3million
- Increased sales across both sectors
- Significant investment of £388,000 (2011: £137,000) in
R&D
- Expansion of product line to include 4 new products
- Break-even in both half-years
- Maiden profit after 16 years
MedSpect
SLIDE 7 7
Security Overview
- Security sales up 119% to £2,954,000 (2011: £1,351,000)
- Successful roll-out of new SVXi vehicle screening product
- First sale of AXIS-100 baggage screening system
- Margin of 35% reflecting sales mix:
– Lower margins on highly competitive baggage screening market – Major elements of the SVXi subcontracted – One-off costs associated with product introductions
SLIDE 8 8
Industrial Overview
- Industrial revenue increased by 64% to £1,348,000 (2011: £ 823,000)
- Developed two additional industrial inspection systems:
– MDXi-200, a more compact, lower cost system – MedSpect, for inspection of small medical devices
- Two new industrial customers with repeat business potential
- Nuclear contract proving to be more costly than originally planned
- Overall Industrial margin at 45%
SLIDE 9
9
Sales Mix by Sector
500 1000 1500 2000 2500 3000 £'000 2005 2006 2007 2008 2009 2010 2011 2012 Financial Years Security Industrial
SLIDE 10
10
Income Statement
2009 2010 2011 2012 Revenue (£’000) 1,444 1,472 2,173 4,302 Gross Margin (%) 48% 55% 41% 38% Overheads (£’000) 1,283 1,218 1,169 1,624 Profit/(Loss) (£’000) (537) (382) (237) 108 EPS (pence) (1.0) (0.6) (0.4) 0.14
SLIDE 11
11
Balance Sheet
£’000 2009 2010 2011 2012 Tangible Assets (£’000) 73 49 44 39 Inventories (‘000) 233 273 315 413 Receivables (‘000) 246 348 596 1,197 Net Cash (£’000) 850 348 945 74 Current Liabilities (£’000) (323) (204) (1,029) (746) Net Assets (£’000) 1,079 814 871 977
SLIDE 12 12
Balance Sheet
- Year-end cash balance of £74,000
- Receivables at £1,197,000 of which £350,000
received within 3 days of the year end
- Current bank balance of £166,000
- RBS overdraft facility of £100,000
- Company remains debt-free
- Investment in inventory continues to support wider
product range
EOD vehicle inspection Drugs in petrol tank
SLIDE 13 13
Commercial Strategy
Since 2009 the Company has adopted a strategy to:
- Establish a range of standard products
- Incrementally develop products to meet market demands
- Invest in new products where commercially justified
- Extend reach in territory through experienced sales team
- Invest in marketing collateral and website
Positive signs that strategy adopted is valid:
- Enhanced volume and quality of sales enquiry pipeline
- Both sectors increasing in revenue and sales
- pportunities
FlatScan-TPXi FlatScan-15
SLIDE 14 14
Product Portfolio
SVXi
2008 2012 Security AXIS-3D AXIS-3D, AXIS-64, AXIS-100, AXIS-53 FlatScan-TPXi FlatScan-TPXi Gen 2 FlatScan-15, ThreatSpect SVXi Industrial MDXi-400, MDXi-NT MDXi-400, MDXi-NT CatSpect, MDXi-200 MedSpect
SLIDE 15 15
Outlook
- Cumulative orders for current financial year of £1,145,000
– Opening order book of £417,000 – New order intake since 1st October of £728,000
- Order intake exceeds that first 5 months last year by 39%
- Increase evident across both sectors
– FlatScan sales reach extended to new territories – Repeat sales of industrial system to a new customer – Industrial opportunities opening up from niche expertise
- However, profitability reliant on securing 2 significant contracts
SLIDE 16 16
Challenges for 2013
- Improve profitability through increased gross margins
- Incremental investment in product range driven by market feedback
- Strong pipeline but sales target for 2013 is challenging
- Build on industrial expertise to secure new business opportunities
- Limited cash resources
- Sustainability of business performance remains the major challenge
SLIDE 17
17
Contact Us Brian Emslie Chairman Louise George CEO Image Scan Holdings plc 3DX-RAY Limited 16-18 Hayhill Industrial Estate Barrow-upon-Soar Leicestershire, LE12 8LD Tel : 01509 817400 Email : ir@ish.co.uk Web : www.ish.co.uk Ticker : ige
SLIDE 18 18
Important Notice
- This document is issued and approved for distribution within the United Kingdom by
Image Scan Holdings plc (the “Company”) only to eligible counterparties and professional clients as defined in the FSA rules. It is not directed at, may not be suitable for and should not be relied upon by any other person. The information in this document is compiled from a number of sources and is believed to be correct, but cannot be guaranteed and should not be relied upon. This document does not constitute or form any part of, and is not to be construed as an offer, invitation or solicitation to buy or sell any securities issued by any of the companies referred to in it. Any opinions expressed are subject to change without notice.
